About Avenue Therapeutics, Inc.
https://www.avenuetx.comAvenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
CEO
Alexandra MacLean
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-04-26 | Reverse | 1:75 |
| 2022-09-23 | Reverse | 1:15 |
Ratings Snapshot
Rating : A-
Price Target
About Avenue Therapeutics, Inc.
https://www.avenuetx.comAvenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 ▼ | $724K ▼ | $-683K ▼ | 0% ▼ | $-0.21 ▼ | $-683K ▼ |
| Q2-2025 | $1.4M ▲ | $1.11M ▼ | $335K ▲ | 23.86% ▲ | $0.11 ▲ | $297K ▲ |
| Q1-2025 | $0 | $1.91M ▲ | $-1.85M ▼ | 0% | $-0.62 ▼ | $-1.91M ▼ |
| Q4-2024 | $0 | $1.6M ▼ | $-1.54M ▲ | 0% | $4.54 ▲ | $-1.56M ▲ |
| Q3-2024 | $0 | $3.16M | $-3.08M | 0% | $-1.92 | $-3.02M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $3.71M ▲ | $3.73M ▼ | $1.42M ▲ | $3.56M ▼ |
| Q2-2025 | $3.33M ▼ | $4.16M ▲ | $1.33M ▲ | $4.06M ▲ |
| Q1-2025 | $3.5M ▲ | $3.59M ▲ | $1.26M ▲ | $3.51M ▲ |
| Q4-2024 | $2.59M ▼ | $2.67M ▲ | $816K ▼ | $2.8M ▲ |
| Q3-2024 | $2.6M | $2.63M | $973K | $2.61M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-698K ▼ | $383K ▲ | $0 | $0 | $383K ▲ | $383K ▲ |
| Q2-2025 | $329K ▲ | $-176K ▲ | $0 | $0 ▼ | $-176K ▼ | $-176K ▲ |
| Q1-2025 | $-1.86M ▼ | $-1.19M ▼ | $0 | $2.09M ▲ | $908K ▲ | $-1.19M ▼ |
| Q4-2024 | $-1.56M ▲ | $-764K ▲ | $0 | $761K ▲ | $-3K ▲ | $-764K ▲ |
| Q3-2024 | $-3.09M | $-2.89M | $0 | $567K | $-2.32M | $-2.89M |
CEO
Alexandra MacLean
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-04-26 | Reverse | 1:75 |
| 2022-09-23 | Reverse | 1:15 |
Ratings Snapshot
Rating : A-